SyntekaBio

SyntekaBio Net Tangible Assets

The Net Tangible Assets of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 31.78 B KRW. In the previous year, Net Tangible Assets was 24.94 B KRW — a change of 27.41% (higher).

Net Tangible Assets

31.78 BKRW

YoY

27.41%

Last updated:

Net Tangible Assets of SyntekaBio is 2025 31.78 B KRW. Net Tangible Assets of SyntekaBio was 2024 24.94 B KRW. It decreases by 27.41% higher compared to the previous year.

The SyntekaBio Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
1.14 B KRW
Jan 1, 2019
45.62 B KRW
Jan 1, 2020
41.07 B KRW
Jan 1, 2021
27.19 B KRW
Jan 1, 2022
30.83 B KRW
Jan 1, 2023
31.23 B KRW
Jan 1, 2024
24.94 B KRW
Jan 1, 2025
31.78 B KRW
The SyntekaBio Net Tangible Assets history
YEARNet Tangible AssetsYoY
31.78 BKRW+27.41%
24.94 BKRW-20.13%
31.23 BKRW+1.30%
30.83 BKRW+13.37%
27.19 BKRW-33.78%
41.07 BKRW-9.99%
45.62 BKRW+3,913.71%
1.14 BKRW-134.31%
-3.31 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Net Tangible Assets of SyntekaBio is 31.78 B KRW in 2025.

Net Tangible Assets of SyntekaBio changed from 24.94 B KRW to 31.78 B KRW, representing a 27.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SyntekaBio

All Key Metrics — SyntekaBio